Answers are grounded in this paper and cite their sources.
Vaborbactam is a novel beta-lactamase inhibitor with activity against important beta-lactamases, in particular, serine carbapenemases, and is currently approved in combination with meropenem as Vabomere for the treatment of complicated urinary tract infections, including pyelonephritis. This combination is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae .
No takes yet. Share an insight, caveat, or question.
Griffith et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: